Spontaneously occurring neurogenic muscle activity in a molluscan visceral smooth muscle (penis retractor muscle of Helix pomatia)—II. Tonic contraction— evidence for a modulatory control of the excitatory motor innervation by central nervous structures

Author(s):  
R.W. Wabnitz
1983 ◽  
Vol 16 (4) ◽  
pp. 280
Author(s):  
J-P.L. Dujardin ◽  
D.N. Stone ◽  
C.D. Forcino ◽  
H.P. Pieper

1978 ◽  
Vol 15 (1) ◽  
pp. 65-79
Author(s):  
Barrie J. Hodgson ◽  
Michael J.K. Harper ◽  
Guillermo Valenzuela

Author(s):  
Manuel Villalón ◽  
Marcela Hermoso ◽  
Mateo Budinich ◽  
Julio Aguilera ◽  
Juan C. Sáez

Author(s):  
Sohaib Khalid Hashmi ◽  
Rachel Helen Ceron ◽  
Robert O Heuckeroth

Visceral smooth muscle is a crucial component of the walls of hollow organs like the gut, bladder, and uterus. This specialized smooth muscle has unique properties that distinguish it from other muscle types and that facilitate robust dilation and contraction. Visceral myopathies are diseases where severe visceral smooth muscle dysfunction prevents efficient movement of air and nutrients though the bowel, impairs bladder emptying, and affects normal uterine contraction and relaxation, particularly during pregnancy. Disease severity exists along a spectrum. The most debilitating defects cause highly dysfunctional bowel, reduced intrauterine colon growth (microcolon), and bladder emptying defects requiring catheterization, a condition called Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS). People with MMIHS often die early in childhood. When the bowel is the main organ affected and microcolon is absent, the condition is known as myopathic chronic intestinal pseudo-obstruction (CIPO). Visceral myopathies like MMIHS and myopathic CIPO are most commonly caused by mutations in contractile apparatus cytoskeletal proteins. Here, we review visceral myopathy-causing mutations and normal functions of these disease-associated proteins. We propose molecular, cellular, and tissue-level models that may explain clinical and histopathological features of visceral myopathy and hope these observations prompt new mechanistic studies.


1998 ◽  
Vol 274 (2) ◽  
pp. H650-H654 ◽  
Author(s):  
David E. Dobbins

Numerous endogenous vasoactive agents have been shown to cause lymphatic smooth muscle contraction. In this study, we assessed the ability of serotonin (5-HT) to alter lymphatic smooth muscle activity and elucidated the receptor mechanisms of 5-HT’s actions. Both intralymphatic and intra-arterial administration of 5-HT significantly increased lymphatic smooth muscle activity in lymphatics perfused at constant flow, as indicated by an increase in lymphatic perfusion pressure. The 5-HT-induced increase in lymphatic perfusion pressure is attenuated but not blocked by the intra-arterial infusion of phentolamine, suggesting the involvement of α-adrenoreceptors and 5-HT receptors. Intralymphatic infusion of the 5-HT2-receptor-agonist α-methylserotonin significantly increased lymphatic perfusion pressure, either alone or when administered into an α-receptor blocked preparation, whereas the 5-HT1-receptor-agonist carboxyamidotryptamine maleate did not effect the prenodal lymphatics. These data indicate that the lymphatic smooth muscle contraction produced by 5-HT is mediated both by lymphatic α-adrenoreceptors and 5-HT2 receptors.


Sign in / Sign up

Export Citation Format

Share Document